BioNTech SEA study recently published in Nature on the use of mRNA “vaccines” targeting cancer neoantigens in triple-negative breast cancer (TNBC) has generated considerable attention in scientific circles. However, with only 14 patients treated in this Phase I trial, it is far too early to declare a breakthrough. Still, the highly encouraging data breathe new life into a cancer vaccine approach that in recent years had fallen behind antibodies, ADCs and checkpoint inhibitors.
Tag Archive for: Cancer vaccination
IO BiotechIO Biotech has published top-line results from its pivotal Phase 3 trial evaluating the therapeutic cancer vaccine IO102-IO103 (Cylembio) in combination with pembrolizumab in patients with advanced melanoma. While the combination achieved a notable improvement in progression-free survival (PFS), the study narrowly missed its predefined statistical threshold for significance.